Can GHK-Cu be combined with retinoids
Fertil Steril 83(1):95103
Over time, this can contribute to hormonal imbalance, including reduced testosterone
Contraindication screening (MTC, MEN 2, GI disease) Eligibility Criteria BMI 30 kg/m BMI 27 kg/m with comorbidities (e.g., hypertension, dyslipidemia, type 2 diabetes) Documentation Medical necessity justification Informed consent Monitoring logs for safety and insurance requirements Patient Selection & Screening The foundation of safety in GLP-1 programs is rigorous screening: Medical history : focus on thyroid cancers, MEN 2, pancreatitis, gallbladder disease, gastroparesis Psychological readiness : assess for eating disorders, severe depression, or substance abuse Laboratory screening : lipase, CMP, thyroid tests (including calcitonin if indicated), HbA1c for diabetes risk Medication Selection & Dosing Strategies Available GLP-1 options: Tirzepatide dual GIP/GLP-1 action, highest average weight loss (1522.5% in trials) Semaglutide proven safety, broad insurance coverage, cardiovascular benefits (1215% weight loss) Liraglutide daily dosing flexibility Dosing principles: Always start low and titrate gradually Adjust schedules for tolerance and patient response Provide clear patient education on dosing and side effect management Comprehensive Monitoring Programs Monitoring is not optional it is essential to safety and success
